Practical guide for the treatment of leishmaniasis.
This article summarises the clinical features of visceral, cutaneous and mucocutaneous leishmaniasis, and leishmaniasis in HIV-coinfected patients. The characteristics and clinical use of pentavalent antimonials and the traditional drugs used in all forms of leishmaniasis are described. There have been important developments in therapy, such as aminosidine (paromomycin) conventional amphotericin B and lipid-associated amphotericin B. In most cases of leishmaniasis there is a range of treatment options which is determined by the geographical and clinical features. This review is intended to assist the clinician in choosing treatment and in using unfamiliar drugs with safety and efficacy.
Davidson
R N
RN
Department of Infection and Tropical Diseases, Lister Unit, Northwick Park Hospital, Harrow, Middlesex, England. r.n.davidson@ic.ac.uk
D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D007371:Interferon-gamma / Q000627:therapeutic use; D007896:Leishmaniasis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000503:physiopathology; D011576:Psychodidae
D000981:Antiprotozoal Agents; D007371:Interferon-gamma